Rejection and hepatitis in liver transplants by Manez, R et al.
0041-133719416712-1824$03.00/0 
TRANSPLANTATION 
Copyright C> 1994 by Williams '" Willtins 
Transplantation® 
LETTERS TO EDITOR 
ABO ANTIBODIES 
I read with great interest the article by Hanto, Brunt, 
Goso, and Cole on the accelerated acute rejection of an ~ 
renal allograft in an 0 recipient (Transplantation 1993; 56: 
1580). I am in complete agreement with the authors' findings 
and am frankly surprised that this event does not occur 
more frequently in ~ to 0 grafts. The presence of high ti-
ters of anti-A are quite common in group 0 individuals due 
to constant antigenic challenge from the environment and 
from A-like substances found in common bacterial vaccines. 
However, since I was an ardent student of the ABO blood 
group system before becoming involved in HLA, it troubles 
me to see someone refer to an anti-J\ antibody. Antibodies of 
such a specificity do not exist. In fact, the ABO blood group 
system has within it two distinct types of anti-A An anti-A!> 
which reacts only with group Al cells, and another antibody 
usually referred to as anti-~n' which reacts with all 
group A red cells and tissues. The anti-~OD antibodies are 
the ones the authors describe. 
CHESTER M. ZMIJEWSKI 
Department of Pathology and Laboratory Medicine 
University of Pennsylvania Medical Center 
Philadelphia, Pennsylvania 19104 
REJECTION AND HEPATITIS IN LIVER TRANSPLANTS 
Roberts et a1. (1) recently described the successful treat-
ment of a liver allograft recipient with azathioprine and pred-
nisone after failed courses ofCsA, FK.506, and RS61443. The 
ostensible diagnosis in their patient was rejection. However, 
the alternative possibility should be considered that the post-
operative graft dysfunction was caused by hepatitis. Their 
patient underwent liver transplantation for cirrhosis second-
ary to hepatitis C and two small foci of hepatocellular carci-
noma. This group has previously reported that recurrence of 
HCV hepatitis after liver transplantation may mimic the 
vanishing bile duct syndrome of rejection (2). 
We also have recent data that support an association be-
tween these 2 conditions. In a study of 738 adults treated 
with cyclosporine from 5/V87 to 7/3V89, 618 recipients (85%) 
who survived beyond the first 3 postoperative months served 
as a study population that now has a mean follow-up of 
1200::':490 (SD) days. Chronic rejection, manifested by the 
vanishing bile duct syndrome was diagnosed in 118 (19%) of 
these patients after a mean 530::':400 posttransplantation 
days. Sixty-three (53%) of the 118 patients had recurrent or 
de novo hepatitis at a mean of 415::':379 posttransplant days 
that was classified "non-A, non-B" in 46 (69%) of the 63 cases. 
In contrast, only 75 (15%) of the 500 patients without the 
vanishing bile duct syndrome ever had the diagnosis ofhepa-
titis. As in the case reported by Roberts et al. (1), the his-
topathologic findings in patients with the dual diagnosis 
overlapping chronic hepatitis and chronic rejection were por-
tal inflammation with bile duct damage involving a variable 
percentage of the ducts present and bile duct loss in <50% of 
the triads. 
During the first clinical trials of FK506 for cases of refrac-
tory rejection (1989-1990), many liver recipients were sent to 
us from all parts of the United States for rescue from "acute" 
or "chronic" rejection. More than a third arrived with errors 
in diagnosis. These included unrecognized technical acci-
dents such as arterial thrombosis or bile duct obstruction, 
lymphoproliferative disorders, and hepatitis due to CMV, 
HBV, or HCV. The first therapeutic adjustment in such cases 
was almost always reduction of immunosuppression. The re-
port by Roberts et a1. (1) would appear to be another such 
example in which the primary diagnosis turned out to have 
been recurrent hepatitis in a patient who was being system-
atically overimmunosuppressed. Recovery occurred when 
this error was corrected. 
RAFAEL MANEZ 
ANTHONY J. DEMETRIS 
THOMAS E. STARZL 
University of Pittsburgh Medical School 
Pittsburgh, Pennsylvania 
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EBER-1 GENE EXPRESSION IN POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE 
In their recent article on Epstein-Barr virus-associated 
disorders (Transplantation 1993; 56: 
Sokal et a1. have quoted work at the University of 
Pit:tst)UI'lZh to suggest that immunosuppression should be 
"
,'lowered as soon as EBER-1 RNA is detected in liver trans-
'plant recipients. It is necessary to clarify that EBER-1 gene 
, '~ression, in itself ~s 0n.ty a ~arker for the presence of la-
·;lent Epstem-Barr VU"US infection. Small numbers of EBER-
* 'l-positive cells can be seen in tissues of healthy seropositive 
,;' individuals (1). It is only a high viral load reflected by a se-
"quential increase in the number of EBER-1-positive cells 
that should serve as a warning sign for the development of 
. posttransplant lymphoproliferative disease. The actual 
< function of EBER-1 RNA is not known with certainty, but 
" there is no firm evidence yet that it is per se important in 
, the pathogenesis of PTLD. Gene deletion experiments have 
shown that the EBER genes are not a prerequisite for B 
lymphocyte transformation in vivo (2). However, it is pos-
sible that EBER molecules could modulate the antiviral ef-
fects of interferons, and thereby create a milieu more favor-
able for survival of the virus in vivo (3, 4). 
PARMJEET S. RANDHAWA 
Division of Transplantation Pathology 
Department of Pathology 
University of Pittsburgh School of MediciTU! 
Pittsburgh, Pennsylvania 15213 
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